Novartis AG (NOVN) Price & Analysis

Compare

32 Followers

NOVN Stock Chart & Stats

CHF100.42

-CHF1.10(-1.10%)

At close: Mar 06 4:00 PM EST

CHF100.42

-CHF1.10(-1.10%)

Day’s Range― - ―

52-Week RangeCHF81.10 - CHF106.88

Previous CloseN/A

Volume858.75K

Average Volume (3M)2.71M

Market Cap

CHF193.14B

Enterprise ValueCHF208.96B

Total Cash (Recent Filing)CHF9.75B

Total Debt (Recent Filing)CHF32.02B

Price to Earnings (P/E)16.3

Beta0.92

Next Earnings

Feb 04, 2026

EPS Estimate

1.58

Last Dividend Ex-Date

Mar 11, 2025

Dividend Yield3.42%

Share Statistics

EPS (TTM)1.80

Shares Outstanding2,112,421,900

10 Day Avg. Volume2,438,245

30 Day Avg. Volume2,709,021

Financial Highlights & Ratios

PEG Ratio-0.99

Price to Book (P/B)4.47

Price to Sales (P/S)3.81

P/FCF Ratio14.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF102.80

Price Target Upside2.37% Upside

Rating ConsensusHold

Number of Analyst Covering12

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market OpportunitiesNovartis highlight bullish KOL feedback given no approved therapies, suggesting a unique market opportunity for their product.

Product PipelineNovartis highlights a busy and promising pipeline of products expected to drive growth beyond 2030.

Sales Growth ForecastNovartis has upgraded its sales growth forecast with a new CAGR of 5-6%, implying higher future sales than previously expected.

Bears Say

Clinical FeedbackKOL feedback seems more cautious, describing the data as underwhelming and suggesting limited clinical use.

Operational Income OutlookFY25 sales and core operational income guides both unchanged, with implied core operational income guide below consensus, suggesting a slower growth outlook.

Valuation ConcernsDespite a promising pipeline and growth potential, the analyst maintains a Neutral rating on valuation, suggesting concerns over the stock's current price relative to its growth forecast.

Novartis AG News

Morning Movers: Walmart gains, Bath & Body Works plummets after Q3 reports

Stock futures are rising after Nvidia delivered another blockbuster earnings report and forward outlook. However, investors must still...

2d ago

ABT

Novartis sees +5%-6% sales CAGR cc for 2025-2030

Novartis (NVS) rolled forward its mid-term guidance to 2025-2030 with a sales CAGR of +5-6% cc. The updated...

2d ago

NVS

Novartis to build manufacturing hub in North Carolina

Novartis (NVS) announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with...

3d ago

NVS

Novartis announces Phase III trial for KLU156 met primary endpoint

Novartis (NVS) announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156. The novel...

9d ago

NVS

Dyne Therapeutics price target lowered to $11 from $13 at Oppenheimer

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Dyne Therapeutics (DYN) to $11 from $13 and...

10d ago

DYN

NVS

FDA appoints Richard Pazdur as Director of CDER

The U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced that Richard...

11d ago

AZN

BMY

Novartis opens radioligand therapy manufacturing facility in California

Novartis (NVS) announced the opening of a new 10,000-square-foot radioligand therapy manufacturing facility in Carlsbad, California. This site...

12d ago

NVS

Novartis upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Novartis (NVS) to Overweight from Equal Weight with a price target of CHF 110, up...

22d ago

NVS

FDA moves to accelerate biosimilar development, lower drug costs

The U.S. Food and Drug Administration on Wednesday announced action to make it faster and less costly to...

23d ago

AZN

BMY

Novartis reports NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective

Novartis (NVS) presented new ianalumab data in Sjogren’s disease at a late-breaker presentation during the American College of...

24d ago

NVS

Novartis AG: Hold Rating Amid Moderate Growth and Valuation Concerns

Analyst Sachin Jain of Bank of America Securities reiterated a Hold rating on Novartis AG, retaining the price...

2d ago

NVS

Cautious Hold on Novartis AG Amid Mixed Ianalumab Data and Valuation Concerns

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novartis AG, retaining the price...

19d ago

NVS

Positive Long-Term Growth Outlook for Novartis AG Amid Temporary Setbacks

In a report released today, Thibault Boutherin from Morgan Stanley upgraded Novartis AG to a Buy, with a...

22d ago

NVS

Cautious Hold Rating on Novartis AG Amid Mixed ianalumab Study Results and Uncertain Growth Prospects

In a report released today, Sachin Jain from Bank of America Securities maintained a Hold rating on Novartis...

26d ago

NVS

NOVN FAQ

What was Novartis AG’s price range in the past 12 months?

Novartis AG lowest stock price was CHF81.10 and its highest was CHF106.88 in the past 12 months.

What is Novartis AG’s market cap?

Novartis AG’s market cap is CHF193.14B.

When is Novartis AG’s upcoming earnings report date?

Novartis AG’s upcoming earnings report date is Feb 04, 2026 which is in 74 days.

How were Novartis AG’s earnings last quarter?

Novartis AG released its earnings results on Oct 28, 2025. The company reported CHF1.804 earnings per share for the quarter, missing the consensus estimate of CHF1.822 by -CHF0.018.

Is Novartis AG overvalued?

According to Wall Street analysts Novartis AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novartis AG pay dividends?

Novartis AG pays a Annually dividend of CHF3.5 which represents an annual dividend yield of 3.42%. See more information on Novartis AG dividends here

What is Novartis AG’s EPS estimate?

Novartis AG’s EPS estimate is 1.58.

How many shares outstanding does Novartis AG have?

Novartis AG has 2,112,421,900 shares outstanding.

What happened to Novartis AG’s price movement after its last earnings report?

Novartis AG reported an EPS of CHF1.804 in its last earnings report, missing expectations of CHF1.822. Following the earnings report the stock price went down -4.159%.

Which hedge fund is a major shareholder of Novartis AG?

Currently, no hedge funds are holding shares in CH:NOVN

Company Description

Novartis AG

Novartis AG is a global healthcare company based in Switzerland that focuses on the research, development, manufacture, and marketing of innovative pharmaceuticals and generic medicines. The company operates in two main sectors: Innovative Medicines, which includes patented pharmaceuticals across various therapeutic areas such as oncology, cardiology, immunology, and neuroscience, and Sandoz, its generic and biosimilar division. Novartis is known for its strong pipeline of drugs, including well-known treatments like Gleevec for cancer and Cosentyx for autoimmune diseases.

Novartis AG (NOVN) Earnings & Revenues

Historic Earnings Reports

NOVN Stock 12 Month Forecast

Average Price Target

CHF102.80

▲(2.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"CHF84","121":"CHF121","93.25":"CHF93.3","102.5":"CHF102.5","111.75":"CHF111.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF102.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF90.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,93.25,102.5,111.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.27,100.86461538461538,102.45923076923077,104.05384615384615,105.64846153846153,107.24307692307693,108.83769230769231,110.43230769230769,112.02692307692308,113.62153846153846,115.21615384615384,116.81076923076924,118.40538461538462,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.27,99.54153846153845,99.81307692307692,100.08461538461538,100.35615384615384,100.6276923076923,100.89923076923077,101.17076923076922,101.4423076923077,101.71384615384615,101.98538461538462,102.25692307692307,102.52846153846154,{"y":102.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,99.27,98.55692307692307,97.84384615384614,97.13076923076923,96.4176923076923,95.70461538461538,94.99153846153845,94.27846153846154,93.56538461538462,92.85230769230769,92.13923076923076,91.42615384615385,90.71307692307693,{"y":90,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":92.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.92,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.29,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.79,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.08,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >